CELL MEDIATED CYTOTOXICITY

体外培养活化杀伤细胞的细胞学基础 抗肿瘤的药物已经部分建立，使用聚肌胞酸 (Poly I）和纯化的重组IL-2作为活化剂。 前体 包括Thy 1+和Thy 1-细胞的细胞被IL-2刺激 并可能通过辅助细胞（巨噬细胞）产生的额外淋巴因子 和/或B细胞）细胞和L3 T4+辅助T细胞。 的产生 抗肿瘤细胞毒性细胞以菌株依赖性方式被抑制， 辅助细胞 总之，低剂量的IL-2和辅助活化 代理（例如，Poly I）产生的抗肿瘤活性水平相当于 高剂量的IL-2单独产生的那些。 人PBL，用IL-2体外活化并用杂交单克隆抗体处理 抗体，阻断人结肠癌细胞在肿瘤中的生长 在裸鼠中的中和测定。 混合分子包括 交联单克隆抗体，其与1）免疫球蛋白Fc反应 受体或与细胞毒性T细胞上的抗原受体复合物 淋巴细胞和2）与人结肠癌细胞。

The cellular basis for in vitro generation of activated killer cells against tumors has been partially established, using polyinosinic acid (Poly I) and purified recombinant IL-2 as the activating agents. Precursor cells, which include both Thy 1+ and Thy 1- cells are stimulated by IL-2 and probably by additional lymphokines produced by accessory (macrophage and/or B cells) cells and L3T4+ helper T cells. The generation of anti-tumor cytotoxic cells is inhibited in a strain-dependent fashion by accessory cells. Together, low doses of IL-2 and ancillary activating agents (e.g., Poly I) generate levels of anti-tumor activity equivalent to those generated by high doses of IL-2 alone. Human PBL, activated in vitro with IL-2 and treated with hybrid monoclonal antibodies, block growth of human colon carcinoma cells in tumor neutralization assays in nude mice. The hybrid molecules consist of cross-linked monoclonal antibodies, which react 1) with immunoglobulin Fc receptors on K cells or with the antigen receptor complex on cytotoxic T lymphocytes and 2) with human colon carcinoma cells.